Clearside Biomedical Inc (CLSD.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2012||Chairman of the Board|
|50||2011||President, Chief Executive Officer, Director|
|52||2012||Chief Financial Officer|
|52||2016||Chief Scientific Officer|
|Vice President - Engineering & Manufacturing|
- BRIEF-Clearside Biomedical Q3 loss per share $0.72
- BRIEF-Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA
- BRIEF-Clearside Biomedical reports Q2 loss per share $0.54
- BRIEF-Clearside Biomedical completes patient enrollment in Phase 3 Peachtree Clinical Trial of CLS-TA
- BRIEF-Clearside Biomedical announces first patient randomized in phase 2 clinical trial of CLS-TA